Research
Hormonal
Ether-linked phosphatidylethanolamines (specifically PE-P and PE-O) are associated with lower insulin resistance (SSPG) and healthier metabolic profiles, contrasting with other lipid classes like Ceramides and TAGs which increase with IR.
Not all phosphatidylethanolamines are equal. Ether-linked forms (PE-P and PE-O) are associated with lower insulin resistance, while standard PEs and Ceramides are linked to higher resistance. This highlights the importance of lipid subclass specificity in metabolic health.
GoodSupportsHIGH confidence
Importantly, to our knowledge, new associations were found, including an association of ether-linked PE (PE-P)—in contrast to PE in general—with lower SSPG levels.
Why this rating
Robust regression analysis controlling for covariates in a large longitudinal cohort.
Source
Dynamic lipidome alterations associated with human health, disease and ageing
Daniel Hornburg et al. · Nature Metabolism · 2023
DOI 10.1038/s42255-023-00880-1
cohort · n=112Cited 230×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Insulin resistance (IR) fundamentally alters the association between specific lipid subclasses and clinical health markers, causing lipid profiles to diverge significantly from those seen in insulin-sensitive (IS) individuals.Good
- During acute respiratory viral infections (RVIs), specific lipid subclasses (small TAGs, LPCs, ether-linked PEs) undergo dynamic, phase-dependent changes that correlate with immune response and energy metabolism shifts.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →